Analysis of in vitro transcriptional events initiating within the region immediately upstream of the aroP coding region has revealed the presence of three promoters, P1, P2, and P3. Both P1 and P2 give rise to mRNA encoding the AroP protein, whereas P3 initiates transcription in the opposite direction. Both P1 and P3 contain UP elements which contribute to promoter strength. Regulation of expression from these three promoters has been examined in vitro by using supercoiled DNA templates and in vivo by using lacZ transcriptional fusions and specific promoter mutants. Expression from P2 is partially repressed by TyrR alone both in vitro and in vivo. Addition of the aromatic amino acid tyrosine, phenylalanine, or tryptophan further increases this repression. P1 is not repressed by TyrR alone but is repressed in vivo in the presence of phenylalanine, tyrosine, or tryptophan. This also occurs in vitro but requires Ca 2؉ ions in the reaction mixture for its demonstration. Under these conditions, transcription from P3 is enhanced by TyrR protein with phenylalanine, tyrosine, or tryptophan. However, we were unable to demonstrate P3 expression in vivo. Under repressing conditions, there is no production of truncated RNA molecules (from P1), which would be expected if repression involved a roadblock mechanism.
In Escherichia coli, the gene aroP encodes an integral membrane protein that transports tyrosine, phenylalanine, and tryptophan into the cell (1) . The aroP gene has been cloned and sequenced (2, 8) , and primer extension analysis has identified its major promoter. The aroP gene is a member of the TyrR regulon (14) , and its expression is repressed by the TyrR protein in conjunction with any one of the three aromatic amino acids tyrosine, phenylalanine, and tryptophan. However, because the binding site for the TyrR repressor is located downstream and outside the putative RNA polymerase binding site for the previously identified promoter, there is some uncertainty about the mechanism of TyrR-mediated repression of aroP. One possibility is that in this case, the binding of the TyrR repressor to the TyrR boxes interferes with RNA chain elongation rather than initiation. Such a model has been advanced to explain the repression of purB expression by PurR repressor (7) . In the case of aroP, this kind of repression would result in the formation of truncated mRNA species of 30 to 50 bases. Another possibility is that the previously identified promoter is not the sole or principal promoter for the expression of aroP and additional promoters are located closer to the TyrR boxes. In order to investigate this situation in more detail, we have used in vitro transcription to look for short, truncated transcripts under conditions of repression and to examine the possibility of other promoters in the aroP regulatory region. In this paper, we describe the identification and analysis of various promoters involved in aroP expression and the use of site-directed mutagenesis in conjunction with aroPlacZ fusions to analyze the contributions of these different promoters to aroP expression.
MATERIALS AND METHODS
Bacterial strains and plasmids. All bacterial strains used in this study were derivatives of E. coli K-12. The strains and plasmids used are listed in Table 1 .
Media and chemicals.
The minimal medium used was prepared from halfstrength buffer 56 described by Monod et al. (13) supplemented with 0.2% glucose and appropriate growth factors. To study regulation, we added tyrosine, phenylalanine, or tryptophan to the minimal medium at a final concentration of 1 mM each. Trimethoprim was used in nutrient and minimal media at final concentrations of 40 and 10 g/ml, respectively. Ampicillin and kanamycin were used at final concentrations of 25 and 10 g/ml, respectively. 5-Bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) was used at a final concentration of 25 g/ml. ␣-35 S-dATP (1, 200 Ci/mmol; 10 mCi/ml) was obtained from Amersham Corporation. [␥-
32 P]ATP (3,000 Ci/mmol; 10 mCi/ml) and [␣-32 P]UTP (3,000 Ci/mmol; 10 mCi/ml) were obtained from NEN-DuPont.
Recombinant DNA techniques. Standard recombinant DNA procedures were performed essentially as described by Sambrook et al. (17) . DNA sequences were determined by the chain termination method described by Sanger et al. (18) with T7 DNA polymerase (Pharmacia).
Site-directed mutagenesis. Oligonucleotides were synthesized on a Pharmacia Gene Assembler Plus apparatus. In vitro mutagenesis with synthesized oligonucleotides was performed on M13tg131 derivatives containing the aroP promoteroperator region from pMU1631 by using commercially available kits (Amersham Corporation and U.S. Biochemical Corporation). Mutations were confirmed by DNA sequencing analysis.
␤-Galactosidase assay. ␤-Galactosidase activity was assayed as described by Miller (12) . Specific activity is expressed in units described in reference 12. The data are the results of at least three independent assays.
In vitro transcription. In vitro transcription reactions were carried out by a method based on the standard single-round conditions described by Igarashi et al. (9, 10) . A mixture of template DNA (0.15 pmol) and RNA polymerase (0.5 pmol) was incubated at 37°C in transcription buffer (45 mM Tris ⅐ acetate, 150 mM KCl, 4.5 mM magnesium acetate, 0.1 mM EDTA, and 0.1 mM dithiothreitol) for 25 min. This pretranscription mixture had a total volume of 35 l and included, when required, TyrR protein (200 nM), ATP (0.2 mM), and tyrosine (1 mM), phenylalanine (1 mM), or tryptophan (1 mM). When added, the final concentration of CaCl 2 was 6 mM. Following incubation, 15 l of start solution (consisting of 1ϫ transcription buffer with 0.67 mg of heparin per ml; 0.53 mM [each] ATP, CTP, and GTP; 0.053 mM UTP; and 2 to 3 Ci of [␣-32 P]UTP) was added to initiate RNA synthesis. Transcription was allowed to proceed for 5 min before the reaction was terminated by addition of 50 l of stop solution (40 mM EDTA and 300 g of E. coli tRNA per ml). Protein was removed from the reaction tubes by phenol extraction, and the synthesized RNA was precipitated with 0.5 volumes of ammonium acetate (7.5 M) and 2.5 volumes of ethanol. Samples were pelleted, resuspended in sequencing dye mix, and loaded onto a 6% sequencing gel. Following electrophoresis, the gels were exposed to Kodak XA-R film at Ϫ70°C for 12 to 24 h.
In vitro primer extension. The RNA for in vitro primer extension was prepared by using 1.5 pmol of aroP template DNA and 5 pmol of RNA polymerase. The resulting transcripts were isolated on a 6% polyacrylamide gel. A 32 Plabelled oligonucleotide probe (0.05 pmol), complementary to the bottom or top strand of aroP fragment, was hybridized to half of each purified RNA sample by mixing in hybridization buffer [80% formamide, 20 mM piperazine-N,NЈ-bis(2-ethanesulfonic acid) (PIPES)-NaOH (pH 6.5), 0.4 M NaCl], and incubation at 85°C for 10 min. The samples were then incubated for a further 4 h at 25°C, pelleted, and resuspended in 20 l of reaction buffer (50 mM Tris-HCl [pH 8.3], 10 mM MgCl 2 , 10 mM dithiothreitol, 60 mM NaCl) containing deoxynucleoside triphosphates at a final concentration of 1 mM. The extension reaction was commenced with the addition of 10 U of avian myeloblastosis virus reverse transcriptase and was allowed to proceed for 1 h at 42°C prior to termination with 150 l of stop solution (0.15 M NaCl, 5 mM EDTA). Extension products were separated on a 6% denaturing polyacrylamide gel next to the sequence tracks which were generated by using an oligonucleotide probe (A or B) as a primer and an M13tg130 derivative (or an M13tg131 derivative) which contains the aroP regulatory region as a template.
RESULTS
In vitro transcription of aroP. The sequence of the aroP regulatory region, including the various features that are referred to in this paper, is shown in Fig. 1 . In order to produce a small supercoiled template for in vitro studies, the 299-bp BglII-BamHI fragment shown in Fig. 1 was cloned into the BamHI site of plasmid pDD3 to form plasmid pMU6270. The pDD3 plasmid has been designed specifically for in vitro transcription experiments and contains two T1 transcription terminators from the E. coli rrnB operon situated 150 bp on each side of the unique BamHI site (20) . The supercoiled molecules of pMU6270 were purified and used as templates in the in vitro transcription experiments. The results of one such experiment are shown in Fig. 2 . Contrary to expectation, three transcripts, two strong and one weak, were found to be generated from the aroP regulatory region (Fig. 2) . One of these, a transcript of 313 bases, corresponded to the one predicted to be formed from the previously identified promoter (designated P1) (3) . The other two transcripts, whose sizes were about 290 and 250 bases, have not previously been reported and must either be generated from previously unidentified promoters, which we have designated P2 and P3, respectively, or be the breakdown products of the transcript from P1.
By adding TyrR protein alone or TyrR protein and each of the three aromatic amino acids to the reaction mixture, it was possible to measure the effects of these additions on the production of each of the three transcripts. As can be seen in Fig.  2 , formation of the transcript from P2 was partially inhibited by TyrR protein alone and totally inhibited if one of the aromatic amino acids was also added to the reaction mixture. In these experiments, formation of the transcript from P1 was not affected by the presence of TyrR protein, with or without the aromatic amino acids. We also observed that the transcript from P3 was sometimes increased in the presence of TyrR and one of the aromatic amino acids (data not shown). However, the enhancement of this transcript was not reproducible from experiment to experiment. We were nevertheless able to obtain enough of this transcript and the other two from a number of gels to carry out primer extension analysis to determine the 5Ј ends of these transcripts.
Primer extension of transcripts obtained in vitro. Each of the three transcripts described above was harvested from sequencing gels and hybridized with two 32 P-labelled oligonucleotides. Oligonucleotide A is complementary to the top strand of the aroP regulatory sequence, and oligonucleotide B is complementary to the bottom strand ( Fig. 1) . After reverse transcription, the extension products were analyzed against a sequence ladder generated from oligonucleotide A or B as a primer. This enabled the 5Ј ends of the transcripts to be identified, as shown in Fig. 3 . The transcripts from P1 and P2 were both extended when oligonucleotide A was used as a primer, and the transcript from P3 was extended only by oligonucleotide B. The transcription start site of P1 was found to be the same as that of the transcript previously identified by Chye and Pittard (3) (data not shown), and that of P2 was located 21 bases further downstream (Fig. 3A) . On the other hand, the transcription start site of P3 is on the opposite strand from P1 and P2 and overlaps the P1 Ϫ35 sequence (Fig. 3B) . The putative Ϫ35 and Ϫ10 regions of P2 and P3 were identified by applying the rules of Hawley and McClure (5), and the proposed positions for these promoters and P1 within the upstream region of aroP are shown in Fig. 1 . Both P1 and P3 show poor agreement with the Ϫ35 consensus hexamer, and the spacing between the putative Ϫ35 and Ϫ10 regions of P3 is not optimal. Inspection of the sequence in Fig. 1 shows that there are AT-rich sequences in the upstream regions of both P1 and P3 which may serve as UP elements for enhancement of transcription of these two promoters (16) .
Isolation of mutants defective in either P1 or P2. In order to determine the relative contributions that P1 and P2 make to the transcription of the aroP message, site-directed mutagenesis was used to disable one or the other of these promoters. The Ϫ35 sequence of P1 was changed from GTGCAT to GCACAT. The Ϫ10 sequence of P1 was changed from TAT TCT to AGTTCT. The Ϫ35 sequence of P2 was changed from TTGATC to TCAATC, and a Ϫ10 mutant was made with the sequence AACCGG instead of AACAAT. After the mutations had been verified by sequencing, these mutant templates were each cloned into pMU2385 to construct transcriptional fusions for in vivo studies and into plasmid pDD3 for in vitro studies.
In vitro studies with promoter mutants. Using different pDD3 derivatives (Table 1) as supercoiled templates, in vitro transcription experiments were carried out as described above for the wild-type template, and the results are shown in Fig. 4 . Both mutant templates with alterations to the P1 promoter (pMU6265 and pMU6266) yield one major transcript (from P2), and the two templates with mutations inactivating the P2 promoter (pUM6268 and pMU6269) yield only one strong transcript from P1. The template pMU6268 also yields a stronger-than-usual transcript from P3.
In vivo studies of transcription from P1 and P2. Along with the wild-type aroP-lacZ fusion plasmid pMU6263, plasmids pMU6257, pMU6258, pMU6260, and pMU6262 with the mutant promoters (for a detailed description of these plasmids, see Table 1 ) were each transformed into a haploid tyrR ϩ strain (JP7740), into a tyrR366 strain with a TyrR null phenotype (JP8042), and into strain JP8042 containing a multicopy tyrR ϩ plasmid (pMU1065). These strains were grown in minimal medium alone and in minimal medium supplemented with each of the three aromatic amino acids and assayed for ␤-galactosidase activity. The results are shown in Table 2 .
In tyrR366 cells, in which no regulation of aroP occurs, inactivation of the P2 promoter by changing the Ϫ10 sequence (pMU6262) only reduces the ␤-galactosidase level to about 80% of that of wild-type cells. Inactivation of the P2 promoter by changing the Ϫ35 region, however, results in an approximately 50% reduction in aroP expression. We hypothesize that the change to the Ϫ35 sequence of P2, because of its proximity to the Ϫ10 sequence of P1, may also be affecting P1 activity. Inactivation of promoter P1 reduces overall aroP expression to less than 20% of that of the wild type, confirming previous observations that in vivo, transcription from P1 is the predominant event (3) . With regard to regulation, it can be seen that expression from both P1 and P2 is strongly repressed in vivo by TyrR protein with either tyrosine or phenylalanine. In the presence of tyrosine, for example, the repressibility of P1 and P2 combined (wild type) is 14-fold for haploid tyrR ϩ and 33-fold for multicopy tyrR ϩ , and the repression of the P1 promoter (pMU6260) shows similar values of 13-and 26-fold. In the case of pMU6262, repression of P1 by either tyrosine or phenylalanine is significantly reduced (this mutant is discussed in more detail in the accompanying paper [19] ).
While there is practically no repression of P1 in minimal medium, under the same conditions, repression of the P2 promoter (for both pMU6257 and pMU6258) is 5.4-to 6-fold in the haploid tyrR ϩ strain and 11-to 14-fold in the multicopy tyrR ϩ strain. In the presence of tyrosine or phenylalanine, the TyrR-mediated repression of P2 is increased to about 20-to 40-fold in the haploid tyrR ϩ strain and about 35-to 50-fold in the strain carrying a multicopy tyrR ϩ plasmid. If the amino acid tryptophan is substituted for phenylalanine or tyrosine in the growth medium, repression of expression from both P1 and P2 can also be observed. In this case, however, the level of repression is significantly less than that observed with tyrosine or phenylalanine. The repression of P1 is about 2-to 4-fold in either the haploid or the multicopy tyrR ϩ background, and the repression of P2 is about 10-to 20-fold and 20-to 30-fold, respectively, in the haploid and multicopy tyrR ϩ backgrounds (Table 2) . Is there an UP sequence associated with promoter P1? Ross et al. (16) have identified an AT-rich sequence in the Ϫ40 to Ϫ60 region of the rrnB P1 promoter which acts as a separable promoter module to significantly stimulate transcription. Such sequences have been referred to as UP elements. It has been shown that stimulation of a promoter by an UP element is prevented by mutations in the carboxyl-terminal region of the ␣ subunit of RNA polymerase (16) .
When RNA polymerase with a truncated ␣ subunit (␣-235) (9, 10) was used in an in vitro assay (performed with the wild-type template pMU6270 in the absence of TyrR protein), transcription from P1 but not P2 was dramatically reduced FIG. 3 . Primer extension analysis to determine the transcription start sites of the RNA products generated from plasmid pMU6270 (wild-type aroP template). The sequence ladders are shown, and the final extension points are indicated (asterisks). (A) Extension generated from the P2 transcript when oligonucleotide A (Fig. 1 ) was used as a primer. (B) Extension generated from the P3 transcript when oligonucleotide B (Fig. 1 ) was used as a primer.
FIG. 4.
In vitro transcription of various aroP templates by wild-type RNA polymerase. Single-round in vitro transcription was performed as described in the legend to Fig. 2 (Fig. 5A, lane  2) . In the same experiment, we also observed a significant reduction in transcription from P3 (Fig. 5A, lane 2) . These results suggested that either or both of these promoters may have associated UP elements. An examination of the Ϫ40 to Ϫ60 regions of both promoters reveals relatively AT-rich sequences that could function as UP sequences. We have tested this in promoter P1 by deleting a 37-bp sequence from positions Ϫ46 to Ϫ82 (relative to the P1 promoter) and measuring the overall effect on promoter activity, using a lacZ transcriptional fusion. The results in Table 3 show that in pMU6310, the overall transcription levels (P1 and P2) were reduced to onequarter of the wild-type levels (in the tyrR366 background), while repression was left largely unchanged (in both haploid and multicopy tyrR ϩ backgrounds). By introducing an additional mutation which disabled the P2 promoter in this construct with a deleted P1 UP element (pMU6314), we were able to show that the transcription activity of P1 was decreased by about 10-fold. These results were also confirmed in an in vitro transcription assay in which a mutant aroP template, with the 37-base sequence containing the putative P1 UP element (pMU6322) deleted, was used (Fig. 5B) . The expression from P1 but not P2 is greatly reduced with this template.
Analysis of the P3 promoter. As described above, some in vitro transcription experiments appeared to show activation of P3 expression by TyrR protein and phenylalanine or tyrosine. However, the effects were weak and not reproducible. Furthermore, in these early experiments, we were unable to demonstrate repression of transcription from P1. In an attempt to solve these problems, we first altered our in vitro assay conditions by either utilizing linear DNA templates or including histone-like host proteins such as HU and IHF in the transcription reaction mixture, but none of these had any impact on these experiments (data not shown). This situation was changed, however, when Ca 2ϩ (6 mM) was added to the reaction mixture (Ca 2ϩ has been shown to facilitate in vitro binding of RNA polymerase to promoters [10a] ). As can be seen in Fig.  6 , under these conditions, TyrR protein and phenylalanine caused a marked activation of P3 expression and a significant repression of expression of P1. Similar results were also obtained with tyrosine and tryptophan.
In order to confirm the identity of the putative P3 promoter, we made two mutant derivatives of aroP with changes in either the Ϫ35 or the Ϫ10 region of P3 (Table 1 ). The DNA fragments containing these two P3 mutations were each cloned into plasmid pDD3. The two resulting plasmids (pMU6320 and pMU6321) were then used to carry out in vitro transcription experiments. As shown in Fig. 7 , under conditions in which P3 is strongly expressed, each of these putative P3 promoter mutations severely inhibits in vitro transcription from P3, suggesting that the putative P3 promoter is the binding site for RNA polymerase.
To analyze P3 transcription in vivo, DNA fragments carrying the putative P3 promoter and the two P3 mutations described above were each introduced into the transcriptional fusion plasmid pMU2385. The resulting plasmids were then each transformed into strain JP8042 (tyrR366) or JP7740 (haploid tyrR ϩ ), and the specific activity of ␤-galactosidase in these strains was measured under conditions shown to repress P1. The wild-type P3 produced very low levels of ␤-galactosidase (approximately 10 Miller units) in either the tyrR366 or the haploid tyrR ϩ background, and the rate of ␤-galactosidase synthesis was not affected by either of the P3 mutations (data not shown). These results suggest that P3 does not function as a productive promoter in vivo.
DISCUSSION
In this study, we have carried out in vitro transcription experiments with a supercoiled aroP template and analyzed the a Units are those defined by Miller (12) . The following strains were used: tyrR366, JP8042; haploid tyrR ϩ , JP7740; and multicopy tyrR ϩ , JP8042/pMU1065. MM, minimal medium; Tyr, minimal medium containing 1 mM tyrosine; Phe, minimal medium containing 1 mM phenylalanine; and Trp, minimal medium containing 1 mM tryptophan. Values in parentheses are fold repression, i.e., the ratio of ␤-galactosidase activity in tyrR366 strain JP8042 to that in tyrR ϩ strains.
transcriptional expression initiated from the region immediately upstream of the aroP gene. We have shown that three transcripts can be produced from the aroP template. The transcriptional origin of each of these has been determined by primer extension. On the basis of these results, coupled with an analysis of the DNA sequence, three promoters (P1, P2, and P3) corresponding to these transcripts have been proposed. Promoter P1 corresponds to the previously identified aroP promoter (3), P2 is positioned 21 bases downstream of P1, and P3 is transcribed in the opposite direction. The identities of these promoters were confirmed by carrying out in vitro transcription experiments with aroP templates which contain various promoter knockout mutations.
To quantify the in vivo contributions of P1 and P2 to the expression of aroP, we have constructed various forms of aroPlacZ fusions (e.g., P1-lacZ and P2-lacZ). In vivo results with these mutants showed that in the tyrR366 background, approximately 80% of transcripts originate from P1 and only about 20% originate from P2. These results do not agree with the in vitro observation that promoters P1 and P2 are of about equal strength. However, we tend to favor the in vivo results, as we could detect only the transcript from the P1 promoter in a primer extension experiment using RNA isolated from cells grown under derepressing conditions (data not shown). Although promoter P1 has a relatively weak Ϫ35 sequence, an associated UP element appears to significantly increase promoter strength.
There was no difficulty in demonstrating TyrR-mediated repression of the P2 promoter in the in vitro system. However, in the case of the major promoter P1, TyrR-mediated repression could be shown only when Ca 2ϩ ions were included in the transcription reaction mixture. The role played by the Ca 2ϩ ions in the TyrR-mediated repression of P1 is unclear, but it is possible that Ca 2ϩ can act as a cofactor for either RNA polymerase or TyrR or that it has an effect on the structure of the supercoiled DNA templates. The fact that the putative RNA polymerase binding site for the P2 promoter overlaps the TyrR boxes probably accounts for the significant repression of P2 in minimal medium, as binding of a TyrR dimer to the strong box (box II) alone could interfere with RNA polymerase binding to P2. This minimal-medium repression would also diminish the overall contribution of P2 to aroP transcription in tyrR ϩ cells in vivo. The P3 promoter contains a weak Ϫ35 sequence and has an unusually high number of bases (19 bp) separating the Ϫ10 and Ϫ35 sequences. The data from the in vitro transcription experiment involving a mutant RNA polymerase (␣-235) suggest the existence of a P3-associated UP element which makes a significant contribution to P3 expression in vitro. Although in the presence of the Ca 2ϩ ion, TyrR protein, and phenylalanine, tyrosine, or tryptophan P3 can cause significant levels of divergent RNA to be synthesized in vitro, no such transcription can be detected in vivo. Nevertheless, as described in the accompanying paper (19) , we see this promoter as playing a vital role in regulation of aroP expression. The positioning of promoters P1, P2, and P3 is such that it seems likely that RNA polymerase bound at any one of these sites would preclude a second RNA polymerase molecule binding to any one of the other sites. We are carrying out further experiments to test this hypothesis.
Work by Zalkin and colleagues has shown that the operator (PurR binding site) of the purB gene of E. coli is 242 bp downstream of the transcriptional start site and overlaps codons 62 to 67 in the structural gene (6) . Further studies involving promoter-swapping experiments and Northern (RNA) blot analysis have indicated that the PurR-mediated repression of purB occurs by a transcriptional roadblock mechanism (7). In a Northern blot experiment, a truncated purB mRNA species was detected. It was hypothesized that this truncated RNA is formed when RNA polymerase meets the PurR repressor bound to the purB operator. Although the relative positions of the TyrR boxes of aroP are such that TyrR protein bound to its recognition site could theoretically interfere with elongation of the RNA chain initiated from principal promoter P1, no sign of the predicted small RNA product could be seen in any in vitro transcription experiments (data not shown). Furthermore, in the Northern blot analysis using RNA isolated from cells under repressing conditions, we failed to detect any truncated aroP mRNA molecules (data not shown). To investigate the mechanism of repression of the aroP P1 promoter, we also made a construct in which a 60-bp fragment was inserted between the FIG. 6. In vitro transcription of pMU6270 (wild-type aroP template). Singleround in vitro transcription was performed as described in the legend to Fig. 2 . The Ca 2ϩ ion was added to a final concentration of 6 mM. transcriptional start site of P1 and the TyrR boxes (at positions ϩ22 and ϩ23 relative to the P1 transcriptional start site). In vivo assays showed that this insertion mutation caused complete loss of TyrR-mediated repression of P1 (data not shown). This result is consistent with the model for P1 repression proposed in the accompanying paper (19) but would not be expected if repression occurs by a roadblock mechanism.
